Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Axial Spondyloarthritis (axSpA) Market Size Changed, over the years?

In the axial spondyloarthritis (axspa) market, significant growth has been observed in recent years. The market, which is projected to rise from $6.08 billion in 2024 to $6.58 billion in 2025, will experience a compound annual growth rate (CAGR) of 8.3%. The past era of growth can be linked to the enhancement of diagnostic criteria, advancements in biological treatment methods, increased awareness of the disease, developments in genetic research, and clinical trial progress.

How Much Will the Axial Spondyloarthritis (axSpA) Market Be Worth in 2029?

The market size for axial spondyloarthritis (axspa) is forecasted to witness rampant growth in the coming years, reaching $9.05 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 8.3%. This potential surge during the forecast period can be credited to progress in identifying biomarkers, personal treatment plans, incorporation of digital healthcare, an increase in treatment alternatives, and supportive healthcare policies. The key market trends expected to shape the future are strategies for early intervention, a focus on patient-centered care, the rise of telemedicine and distance consultations, exploration into the mechanisms of the disease, and collective decision-making.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12590&type=smp

Which is the Largest Company in the Axial Spondyloarthritis (axSpA) Market?

Major companies operating in the axial spondyloarthritis (axSpA) market include Johnson and Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca plc., Abbott Laboratories, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Boehringer Ingelheim International GmbH., Horizon Therapeutics Public Ltd Co, Mitsubishi Tanabe Pharma Corporation, Ipsen Technologies Pvt Ltd., Kyowa Kirin Co. Ltd., Sun Pharmaceutical Industries Ltd., Acelyrin Inc., Nordic Bioscience A/S, Iroko Pharmaceuticals LLC

What Are the Main Market Drivers in the Axial Spondyloarthritis (axSpA) Industry?

The proliferation of spondyloarthritis is projected to boost the axial spondyloarthritis (axSpa) market’s expansion. Spondyloarthritis is a long-term disease that predominantly affects the axial skeleton, including the spine and sacroiliac joints. The surge in spondyloarthritis (axSpA) instances is linked with the growing older population and injuries to the spine from minor falls or other incidents. Various treatments are offered for managing pain, controlling inflammation, and improving the life quality of those living with axSpA. For example, Versus Arthritis’s Musculoskeletal Health Report 2023 in June 2023, a charity based in the UK committed to aiding those with arthritis, noted that as of 2022, about 60,000 people were dealing with axial spondyloarthritis, with roughly 2,200 adults being newly diagnosed each year. Consequently, the rising instances of axial spondyloarthritis (axSpa) are fueling the expansion of the axial spondyloarthritis (axSpa) market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12590&type=smp

How Is the Axial Spondyloarthritis (axSpA) Market Segments Structured?

The axial spondyloarthritis (axSpA) market covered in this report is segmented –

1) By Types: Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

2) By Commercialized Therapies: Anti-Tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)

3) By Dosage Form: Tablets, Injections

4) By Treatment: Tumor Necrosis Factor (TNF) Alpha Inhibitors, Non-Steroidal Anti-Inflammatory Drugs (NSAID), Conventional Disease Modifying Anti-Rheumatic Drugs, Glucocorticoids, Interleukin Blockers

5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores

Subsegments:

1) By Ankylosing Spondylitis (AS): Early-stage AS, Advanced-stage AS

2) By Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Symptomatic nr-axSpA, Asymptomatic nr-axSpA

What Strategic Trends Are Transforming the Axial Spondyloarthritis (axSpA) Market?

The primary trend observed in the axial spondyloarthritis (axSpA) market is product innovation. Major players in this market are focusing on developing new pharmaceuticals to maintain their standing. An example of this is when UCB SA, a pharmaceutical firm based in Belgium, obtained marketing approval for its new drug, BIMZELX (bimekizumab), from the New European Commission in June 2023. This drug is prescribed for adults suffering from axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) who show objective inflammation signs indicated by increased C-reactive protein levels. These authorizations by the European Union (EU) mark the first worldwide licenses for the drug for treating axial spondyloarthritis.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

Which Global Regions Offer the Highest Growth in the Axial Spondyloarthritis (axSpA) Market?

North America was the largest region in the axial spondyloarthritis(axSpA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axSpA) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12590

This Report Delivers Insight On:

1. How big is the axial spondyloarthritis (axspa) market, and how is it changing globally?

2. Who are the major companies in the axial spondyloarthritis (axspa) market, and how are they performing?

3. What are the key opportunities and risks in the axial spondyloarthritis (axspa) market right now?

4. Which products or customer segments are growing the most in the axial spondyloarthritis (axspa) market?

5. What factors are helping or slowing down the growth of the axial spondyloarthritis (axspa) market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model